Skip to main content
SpringerLink
Log in

Breast Cancer

  • Chapter
  • First Online:
Book cover Clinical PET and PET/CT

  • 2699 Accesses

Abstract

In 2003, breast cancer was the most frequently diagnosed cancer (212,600 new cases), and the second leading cause of cancer death (40,200 deaths) in American women (Jemal A, Thomas A, Murray T, et al. Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23–47). In women ages 40–55 years, breast cancer is the leading cause of mortality (Jemal A, Thomas A, Murray T, et al. Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23–47). There has been a slight decline in breast cancer mortality overall (Jemal A, Thomas A, Murray T, et al. Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23–47) that can be attributed both to the success of early detection and to advanced treatment, particularly systemic therapy. Caucasian women in the US have a 13.1% lifetime incidence of developing breast cancer, whereas African-American women have a 9.6% lifetime incidence (Jemal A, Thomas A, Murray T, et al. Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23–47). However, the lifetime risk of dying from breast cancer is 3.4% for both African-American and Caucasian women in the U.S. While the incidence of invasive breast cancer has leveled off, the number of ductal carcinomas in situ (DCIS) has been on the rise, probably a result of the increasing use of screening mammography.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Thomas A, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2002;52:23–47.

    Article  PubMed  Google Scholar 

  2. Kopans DB. The positive predictive value of mammography. AJR Am J Roentgenol. 1992;1158:521–6.

    Google Scholar 

  3. Stavros AT, Thickman D, Sisney GA, et al. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology. 1995;196:123–33.

    PubMed  CAS  Google Scholar 

  4. Amano S, Inoue T, Tomiyoshi K, et al. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med. 1998;39:1424–7.

    PubMed  CAS  Google Scholar 

  5. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by F-18 FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9–16.

    PubMed  CAS  Google Scholar 

  6. Crippa F, Seregini E, Agresti R, et al. Association between F-18 flurodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer; a preliminary observation. Eur J Nucl Med. 1998;25:1429–34.

    Article  PubMed  CAS  Google Scholar 

  7. Paramagul CP, Helvic MA, Adler DD. Invasive lobular carcinoma: sonographic appearance and role of sonography in improving diagnostic sensitivity. Radiology. 1995;195:231–4.

    PubMed  CAS  Google Scholar 

  8. Brown RS, Leung JY, Fisher SJ, et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma. Are inflammatory cells important? J Nucl Med. 1995;36:1854–61.

    PubMed  CAS  Google Scholar 

  9. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. J Nucl Med. 1996;37:502–6.

    PubMed  CAS  Google Scholar 

  10. Haberkorn U, Strauss LG, Reisser C, et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med. 1991;32:1548–55.

    PubMed  CAS  Google Scholar 

  11. Burgman P, O’Donoghue JA, Humm JL, et al. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med. 2001;42:170–5.

    PubMed  CAS  Google Scholar 

  12. Wahl RL, Helvie MA, Chang AE, et al. Detection of breast cancer in women after augmentation mammoplasty using F-18 fluorodeoxyglucose PET. J Nucl Med. 1994;35:872–5.

    PubMed  CAS  Google Scholar 

  13. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med. 1998;28:290–302.

    Article  PubMed  CAS  Google Scholar 

  14. Avril N, Dose J, Jäniicke F, et al. Assessment of axillary lymph node involvement in breast patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst. 1996;88:1204–9.

    Article  PubMed  CAS  Google Scholar 

  15. Utech CI, Young CS, Winter PF. Prospective evaluation of F-18 FDG PET in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med. 1997;23:1588–93.

    Article  Google Scholar 

  16. Hoh K, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using F-18 FDG. J Comput Assist Tomogr. 1993;17:582–289.

    Article  PubMed  CAS  Google Scholar 

  17. Haberkorn U, Reinhardt M, Strauss LG, et al. Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. J Nucl Med. 1992;33:1981–7.

    PubMed  CAS  Google Scholar 

  18. Minn H, Soini I. F-18 FDG scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med. 1989;15:61–6.

    Article  PubMed  CAS  Google Scholar 

  19. Jansson T, Westlin JE, Ahlstrom H, et al. PET studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol. 1995;13:1470–744.

    PubMed  CAS  Google Scholar 

  20. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with F-18 FDG in breast cancer. J Nucl Med. 1996;37:931–8.

    PubMed  CAS  Google Scholar 

  21. Vranjesevic D, Filmont JE, Meta J, et al. Whole-body F-18 FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 2002;43:325–9.

    PubMed  Google Scholar 

  22. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in ­estrogen receptor positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992;10:1284–91.

    PubMed  CAS  Google Scholar 

  23. McGuire AH, Dehdashti F, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast assays. J Nucl Med. 1995;36:1766–74.

    Google Scholar 

  24. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer. Comparison with FDG PET and in vitro receptor assays. J Nucl Med. 1995;36:1766–74.

    PubMed  CAS  Google Scholar 

  25. Butler JA, Trezona T, Vargas H, et al. Value of measuring hormone receptor levels of regional metastatic carcinoma of the breast. Arch Surg. 1989;124:1131–6.

    Article  PubMed  CAS  Google Scholar 

  26. Welch MJ, Bonasera TA, Sherman EIC, et al. F-18 FDG and 162-(F-18) fluoroestradiol-17B (FES) uptake in estrogen-receptor (ER)-rich tissues following tamoxifen treatment: a preclinical study. J Nucl Med. 1995;36:39–44.

    Google Scholar 

  27. Wahl RL, Cody R, Fisher S. Uptake before and after estrogen receptor stimulation: feasibility studies for functional receptor imaging. J Nucl Med. 1991;32:1011–5.

    Google Scholar 

  28. Dehdashti F, Flanagan FL, Siegel BA. PET assessment of metabolic flare in advanced breast cancer. Radiology. 1997;205:220–5.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Nuclear Medicine and Diagnostic Radiology, The University of Texas MD Anderson Cancer Center and Medical School, Houston, TX, 77030, USA

    E. Edmund Kim M.D., M.S.

  2. Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea

    E. Edmund Kim M.D., M.S.

  3. Department of Radiology, School of Medicine, Gunma University, Ihara Shizouka, 421-3306, Japan

    Masashi Yukihiro M.D., Ph.D.

Authors
  1. E. Edmund Kim M.D., M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masashi Yukihiro M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Edmund Kim M.D., M.S. .

Editor information

Editors and Affiliations

  1. and Diagnostic Radiology, The University of Texas, Departments of Nuclear Medicine, Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    E. Edmund Kim

  2. Gachon University School of Medicine, Department of Nuclear Medicine, Guwol-dong 1198, Namdong-Gu, Incheon, 405, Korea, Republic of (South Korea)

    Myung-Chul Lee

  3. Yokohama City University, Graduate School of Medicine, Department of Radiology, Fukuura 3-9, Yokohama, Kanagawa, 236-0004, Japan

    Tomio Inoue

  4. The University of Texas, MD Anderson Cancer Center, Dept. of Experimental Diagnostic Imaging, Holcombe Blvd. 1400, Houston, 77030, Texas, USA

    Wai-Hoi Wong

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kim, E.E., Yukihiro, M. (2013). Breast Cancer. In: Kim, E., Lee, MC., Inoue, T., Wong, WH. (eds) Clinical PET and PET/CT. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0802-5_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0802-5_18

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-0801-8

  • Online ISBN: 978-1-4419-0802-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation